Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
The cereblon E3 ligase modulator cemsidomide showed activity against multiple myeloma and two types of non–Hodgkin lymphoma in a phase I study.
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the chemotherapy ...
Innovent Biologics’ ROS1 tyrosine kinase inhibitor (TKI) taletrectinib adipate (Dovbleron) was approved by the National Medical Products Administration, the Chinese equivalent of the FDA, for patients ...
1Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Res (2024) 84 (24): 4298.
Major Finding: Pharmacologic inhibition of EZH2 sensitizes preclinical models of B cell lymphoma to T-cell immunotherapy. Concept: EZH2 inhibition enhances T-cell recruitment, T-cell–B-cell ...
The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The decision was ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...
Machine learning could better stratify patients with metastatic ER-positive, HER2-negative breast cancer who are more or less likely to benefit from CDK4/6 inhibition up front. At Memorial Sloan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback